NKMAXBio

NKMax is a clinical-stage biotechnology company specializing in the development of autologous and allogeneic natural killer (NK) cell therapies for oncology and neurodegenerative diseases. The company utilizes its proprietary SuperNK (SNK) platform technology to produce highly active and pure NK cells with enhanced cytotoxicity and proliferation capabilities. Their lead candidate, SNK01, is currently being evaluated in clinical trials for various indications, including non-small cell lung cancer and Alzheimer's disease. NKMax operates globally with significant research and manufacturing facilities in South Korea and the United States, aiming to provide innovative immunotherapy solutions for patients with high unmet medical needs.